These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37149951)

  • 1. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.
    Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A
    Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial.
    Mercuri E; Muntoni F; Baranello G; Masson R; Boespflug-Tanguy O; Bruno C; Corti S; Daron A; Deconinck N; Servais L; Straub V; Ouyang H; Chand D; Tauscher-Wisniewski S; Mendonca N; Lavrov A;
    Lancet Neurol; 2021 Oct; 20(10):832-841. PubMed ID: 34536405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy.
    McMillan HJ; Proud CM; Farrar MA; Alexander IE; Muntoni F; Servais L
    Expert Opin Biol Ther; 2022 Sep; 22(9):1075-1090. PubMed ID: 35437095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial.
    Day JW; Finkel RS; Chiriboga CA; Connolly AM; Crawford TO; Darras BT; Iannaccone ST; Kuntz NL; Peña LDM; Shieh PB; Smith EC; Kwon JM; Zaidman CM; Schultz M; Feltner DE; Tauscher-Wisniewski S; Ouyang H; Chand DH; Sproule DM; Macek TA; Mendell JR
    Lancet Neurol; 2021 Apr; 20(4):284-293. PubMed ID: 33743238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene transfer therapy in children with spinal muscular atrophy: A single-center experience with a cohort of 25 children.
    Chencheri N; Alexander G; Nugud A; Majadas E; Salim H; Prudhomme K; DeJager N; Janardhanan VS; Elbashir H
    Muscle Nerve; 2023 Sep; 68(3):269-277. PubMed ID: 37392188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
    Pascual-Morena C; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Martínez-Vizcaíno V
    Hum Gene Ther; 2023 Feb; 34(3-4):129-138. PubMed ID: 36136906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onasemnogene abeparvovec gene replacement therapy for the treatment of spinal muscular atrophy: a real-world observational study.
    Bitetti I; Lanzara V; Margiotta G; Varone A
    Gene Ther; 2023 Aug; 30(7-8):592-597. PubMed ID: 35606491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Outcomes in Patients with Spinal Muscular Atrophy Treated with Onasemnogene Abeparvovec Monotherapy: Findings from the RESTORE Registry.
    Servais L; Day JW; De Vivo DC; Kirschner J; Mercuri E; Muntoni F; Proud CM; Shieh PB; Tizzano EF; Quijano-Roy S; Desguerre I; Saito K; Faulkner E; Benguerba KM; Raju D; LaMarca N; Sun R; Anderson FA; Finkel RS
    J Neuromuscul Dis; 2024; 11(2):425-442. PubMed ID: 38250783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1381-1389. PubMed ID: 35715566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological and clinical profile of Onasemnogene Aveparvovec, the first gene therapy for spinal muscular atrophy (SMA)].
    Atsumi A; Yoneda T; Tsuchida K; Kagawa Y; Tominaga S; Kawase K; Kikuchi N
    Nihon Yakurigaku Zasshi; 2022; 157(1):53-61. PubMed ID: 34980814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for spinal muscular atrophy: the Qatari experience.
    Ali HG; Ibrahim K; Elsaid MF; Mohamed RB; Abeidah MIA; Al Rawwas AO; Elshafey K; Almulla H; El-Akouri K; Almulla M; Othman A; Musa S; Al-Mesaifri F; Ali R; Shahbeck N; Al-Mureikhi M; Alsulaiman R; Alkaabi S; Ben-Omran T
    Gene Ther; 2021 Nov; 28(10-11):676-680. PubMed ID: 34276047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Wigderson M; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1390-1397. PubMed ID: 35715567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Onasemnogene abeparvovec-xioi: a gene replacement strategy for the treatment of infants diagnosed with spinal muscular atrophy.
    Schwartz M; Likhite S; Meyer K
    Drugs Today (Barc); 2021 Jun; 57(6):387-399. PubMed ID: 34151905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life.
    Steffens P; Weiss D; Perez A; Appel M; Weber P; Weiss C; Stoltenburg C; Ehinger U; von der Hagen M; Schallner J; Claussen B; Lode I; Hahn A; Schuler R; Ruß L; Ziegler A; Denecke J; Johannsen J
    Eur J Paediatr Neurol; 2024 Jul; 51():17-23. PubMed ID: 38772209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polysomnography findings and respiratory muscle function in infants with early onset spinal muscular atrophy after gene replacement as monotherapy: A prospective study.
    Barrois R; Griffon L; Barnerias C; Gitiaux C; Desguerre I; Fauroux B; Khirani S
    Sleep Med; 2024 Jul; 119():335-341. PubMed ID: 38749258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2024 update: European consensus statement on gene therapy for spinal muscular atrophy.
    Kirschner J; Bernert G; Butoianu N; De Waele L; Fattal-Valevski A; Haberlova J; Moreno T; Klein A; Kostera-Pruszczyk A; Mercuri E; Quijano-Roy S; Sejersen T; Tizzano EF; van der Pol WL; Wallace S; Zafeiriou D; Ziegler A; Muntoni F; Servais L
    Eur J Paediatr Neurol; 2024 Jul; 51():73-78. PubMed ID: 38878702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes.
    Waldrop MA; Karingada C; Storey MA; Powers B; Iammarino MA; Miller NF; Alfano LN; Noritz G; Rossman I; Ginsberg M; Mosher KA; Broomall E; Goldstein J; Bass N; Lowes LP; Tsao CY; Mendell JR; Connolly AM
    Pediatrics; 2020 Sep; 146(3):. PubMed ID: 32843442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
    D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
    Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.